Bulevirtide vs Lanreotide
Overview
Bulevirtide is primarily a antiviral peptide, while Lanreotide is used for hormonal.
This page compares Bulevirtide and Lanreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bulevirtide | Lanreotide | |
|---|---|---|
| Category | Antiviral | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | — | 60-120 mg |
| Frequency | — | every 4 weeks |
| Reported benefits | — | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones |
| Reported side effects | — | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases |
Key differences
Primary use. Bulevirtide is categorised under Antiviral, while Lanreotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bulevirtide: FDA-approved. Lanreotide: FDA-approved.
Dosing. Typical dosing for Bulevirtide is not catalogued. Lanreotide is typically dosed at 60-120 mg (every 4 weeks).
Can you stack them?
Some protocols combine peptides, but stacking Bulevirtide and Lanreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bulevirtide and Lanreotide?
- Bulevirtide is primarily a antiviral peptide, while Lanreotide is used for hormonal. Bulevirtide is FDA-approved for one or more indications, whereas Lanreotide is FDA-approved for one or more indications.
- What is Bulevirtide used for?
- First/only FDA-approved treatment for chronic hepatitis delta virus (HDV). FDA accelerated approval May 22, 2026. Brand: Hepcludex (Gilead).
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- Can you take Bulevirtide and Lanreotide together?
- Some users combine peptides within a single protocol, but stacking Bulevirtide and Lanreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bulevirtide or Lanreotide FDA-approved?
- Bulevirtide is FDA-approved for one or more indications. Lanreotide is FDA-approved for one or more indications.
Read the full articles
- Bulevirtide — full monograph: mechanism, research, dosing & references
- Lanreotide — full monograph: mechanism, research, dosing & references